Evelo Biosciences Inc
NASDAQ:EVLO
Cash Flow Statement
Cash Flow Statement
Evelo Biosciences Inc
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||||||||||||||||
Net Income |
(28)
|
(33)
|
(42)
|
(50)
|
(57)
|
(67)
|
(73)
|
(78)
|
(85)
|
(88)
|
(88)
|
(87)
|
(94)
|
(99)
|
(110)
|
(123)
|
(122)
|
(124)
|
(123)
|
(120)
|
(115)
|
(110)
|
(101)
|
(82)
|
|
Depreciation & Amortization |
1
|
1
|
2
|
2
|
2
|
2
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
Stock-Based Compensation |
2
|
2
|
4
|
6
|
6
|
7
|
7
|
8
|
8
|
8
|
8
|
8
|
8
|
10
|
11
|
14
|
16
|
17
|
17
|
16
|
15
|
14
|
12
|
0
|
|
Other Non-Cash Items |
2
|
2
|
5
|
6
|
7
|
8
|
7
|
8
|
8
|
9
|
10
|
10
|
11
|
12
|
17
|
19
|
21
|
22
|
19
|
20
|
21
|
19
|
19
|
19
|
|
Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Cash Interest Paid |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
3
|
3
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
|
Change in Working Capital |
2
|
2
|
3
|
3
|
1
|
0
|
2
|
0
|
3
|
4
|
2
|
2
|
8
|
5
|
12
|
13
|
2
|
(0)
|
(9)
|
(9)
|
(10)
|
(4)
|
(7)
|
(12)
|
|
Cash from Operating Activities |
(23)
N/A
|
(27)
-17%
|
(33)
-20%
|
(40)
-21%
|
(47)
-20%
|
(57)
-20%
|
(61)
-8%
|
(68)
-11%
|
(72)
-5%
|
(74)
-2%
|
(75)
-1%
|
(73)
+2%
|
(73)
+0%
|
(80)
-9%
|
(79)
+1%
|
(88)
-11%
|
(97)
-10%
|
(99)
-3%
|
(110)
-11%
|
(106)
+4%
|
(101)
+4%
|
(93)
+9%
|
(86)
+7%
|
(74)
+14%
|
|
Investing Cash Flow | |||||||||||||||||||||||||
Capital Expenditures |
(2)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(4)
|
(4)
|
(3)
|
(3)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
0
|
(1)
|
(0)
|
(0)
|
(0)
|
|
Other Items |
0
|
0
|
0
|
(84)
|
(55)
|
(24)
|
(4)
|
85
|
55
|
24
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Cash from Investing Activities |
(2)
N/A
|
(3)
-49%
|
(3)
-31%
|
(89)
-2 513%
|
(60)
+32%
|
(29)
+52%
|
(8)
+73%
|
81
N/A
|
52
-36%
|
21
-59%
|
2
-92%
|
(1)
N/A
|
(1)
+4%
|
(1)
+9%
|
(2)
-52%
|
(2)
-30%
|
(1)
+38%
|
(1)
+11%
|
(1)
+45%
|
0
N/A
|
(1)
N/A
|
(0)
+23%
|
(0)
+50%
|
0
N/A
|
|
Financing Cash Flow | |||||||||||||||||||||||||
Net Issuance of Common Stock |
49
|
98
|
166
|
166
|
157
|
76
|
(9)
|
(9)
|
1
|
0
|
49
|
49
|
55
|
138
|
89
|
90
|
83
|
1
|
79
|
80
|
85
|
85
|
6
|
29
|
|
Net Issuance of Debt |
0
|
5
|
5
|
5
|
5
|
0
|
0
|
4
|
4
|
0
|
0
|
10
|
10
|
0
|
25
|
15
|
15
|
0
|
0
|
0
|
(3)
|
0
|
0
|
(8)
|
|
Other |
(0)
|
(1)
|
(9)
|
(9)
|
(0)
|
1
|
9
|
9
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
|
Cash from Financing Activities |
49
N/A
|
102
+108%
|
163
+60%
|
162
0%
|
162
+0%
|
77
-53%
|
(0)
N/A
|
5
N/A
|
5
+4%
|
5
-1%
|
54
+982%
|
59
+10%
|
65
+11%
|
148
+125%
|
114
-23%
|
104
-8%
|
98
-7%
|
15
-84%
|
79
+418%
|
80
+0%
|
82
+2%
|
81
0%
|
2
-97%
|
21
+839%
|
|
Change in Cash | |||||||||||||||||||||||||
Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(0)
|
(0)
|
(0)
|
1
|
|
Net Change in Cash |
24
N/A
|
72
+201%
|
127
+76%
|
34
-73%
|
55
+62%
|
(9)
N/A
|
(70)
-668%
|
17
N/A
|
(15)
N/A
|
(47)
-214%
|
(19)
+60%
|
(15)
+19%
|
(9)
+42%
|
67
N/A
|
33
-50%
|
14
-57%
|
(1)
N/A
|
(85)
-12 642%
|
(32)
+63%
|
(27)
+15%
|
(21)
+24%
|
(12)
+41%
|
(84)
-594%
|
(52)
+38%
|
|
Free Cash Flow | |||||||||||||||||||||||||
Free Cash Flow |
(25)
N/A
|
(30)
-19%
|
(36)
-21%
|
(44)
-22%
|
(53)
-20%
|
(62)
-18%
|
(66)
-6%
|
(72)
-10%
|
(75)
-4%
|
(76)
-1%
|
(77)
-1%
|
(74)
+3%
|
(74)
+0%
|
(81)
-9%
|
(81)
+0%
|
(90)
-12%
|
(98)
-9%
|
(101)
-3%
|
(111)
-10%
|
(106)
+5%
|
(102)
+4%
|
(93)
+9%
|
(86)
+7%
|
(74)
+14%
|